Navigation Links
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Date:6/16/2008

Data published in the Journal of the American Society of Hypertension

demonstrate that early blockade of angiotensin II reversed vascular

hypertrophy

PARSIPPANY, N.J., June 16 /PRNewswire/ -- A new study published in the current Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, titled VIOS (Vascular Improvement with Olmesartan medoxomil Study) was a one-year, exploratory study that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.(1)

In the VIOS trial, olmesartan medoxomil, through early blockade of angiotensin II, improved the structure abnormalities of resistance arteries in patients with hypertension as measured by arterial wall to lumen ratio (W/L), returning arterial architecture to normal levels after one year of treatment. This protective effect was not seen with the comparator agent in the study, atenolol.(2) Olmesartan medoxomil is marketed in the United States by Daiichi Sankyo, Inc., as BENICAR(R). BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy. BENICAR and BENICAR HCT have not been FDA approved for other indications such as end organ disease or other hypertension related morbidity.

"We believe the VIOS data add to the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular damage at many stages during this disease process," said Carlos M. Ferrario, M.D., one of the study's lead inve
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Pharmaxis Long-Term Safety Study of Bronchitol Completes
4. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
7. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
10. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
11. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... Spinal Cord,Injury Model With ZFP TF Treatment, RICHMOND, ... announced today the presentation of preclinical,data from its ... Annual Conference of the American Society for Neural,Therapy ... of spinal cord,injury (SCI), demonstrate that treatment of ...
... 2007 /PRNewswire-FirstCall/ --,Citing issues related to potentially ... has concluded that the COSTAR,II (CObalt Chromium ... study for the CoStar cobalt chromium,paclitaxel-eluting coronary ... trial did not identify safety issues, and ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 2Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 3Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 4Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 2Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 3Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 4
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... THURSDAY, Oct. 23, 2014 (HealthDay News) -- A large ... West Africa is to avoid tens of thousands of ... Yale University researchers predict. Using a specially ... future of the outbreak in just one densely populated ... the capital city of Monrovia. The researchers said ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
(Date:10/22/2014)... MI (PRWEB) October 22, 2014 ... Schools of Allied Health Professions (ASAHP) Conference on October ... and CEO will participate in a panel discussion on ... Practice. , Isabel Healthcare provides a diagnostic decision support ... improving the diagnosis skills of students and clinical learners. ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... centres will soon need to be registered and also adhere ... a new draft ‘Clinical Establishment Bill’ that has been finalised ... cabinet for approval. ,The proposed law will apply ... or Ayurvedic and the same parameters will apply to a ...
... scientists have successfully grown large numbers of stem cells taken ... to repair some of the tissue// damage done to those ... in humans, making them a useful model in such research. ... a thin tube to extract samples of heart tissue no ...
... proposes to link-up with tour operators to design tour ... and recreation in// the itinerary of tourists. ... secretary for Sports and Wellness of the Department of ... (Philippine Travel Agencies Association) and Naitas (The National Association ...
... Pharmaceutical Technology, Jadavpur University, Kolkata and Department of ... a// study on Plumeria Acuminata leaves. The objective ... anti-inflammatory activity of methanol extract of leaves of ... inflammation in rat hind paw oedema models. ...
... Science Award from Keio University in Tokyo. Mr. Steitz, ... received the award in a ceremony and commemorative symposium conducted ... award, made to researchers in recognition of their outstanding achievements ... only prize of its kind awarded by a Japanese University. ...
... who react slowly and possess bad memories are more prone ... ,Dr.Beverly Shipley, aged 28, from the Psychology dept., Edinburgh University ... heart attacks may be linked. She surveyed the mental agility ... all over Britain. ,She says that those with ...
Cached Medicine News:Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 2Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 3Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2Health News:Yale Scientist Received Medical Science Prize From Keio University 2
... 2 O W/O Adapter., ... humidifier systems feature a dual-purpose reservoir with a ... secure attachment of a humidifier adapter. The oxygen ... reaching oxygen delivery tubing. An audible relief valve ...
... EMPTY W/AIR ENT 35%-100% FIO2, ,Empty ... 35% to 100%. It has ports for ... ,Empty Nebulizers 5007P and 5207 have ... , ,Convenient slip-on heaters are also ...
... , One device provides ... therapy from a single gas source ... decreasing the number of SKUs dedicated ... and inconvenience of double or wye ...
MISTY OX® Hi-Fi Nebulizer...
Medicine Products: